Genmab-chief: ”We have a potential blockbuster in Arzerra”
New, positive data from a phase III study with leukaemia drug Arzerra pleases Genmab’s CEO, Jan Van de Winkel. But he reclines from commenting on the analyst consensus which puts sales just shy of USD 300 million by 2017.
Benjamin Werner Christensen
There are still high hopes for sales growth for Arzerra in coming years, and consensus is at DKK 1.7 billion (USD 299 million), according to major German bank, Deutsche Bank. That is triple the current level, as Arzerra – which is licensed to drug giant GlaxoSmithKline - sold for DKK 552 million (USD 97 million) in 2012. DKK 111 million (USD 19.5 million) of that was passed on to Genmab through a royalty agreement.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Genmab to expand Arzerra
For abonnenter
.jpg&w=384&q=75)
